ETFS Holding Sarepta Therapeutics Inc

 
Stock Quotes for Sarepta Therapeutics Inc top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for srpt investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for srpt investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for ab3a investment picks

 
News Articles for Sarepta Therapeutics Inc top ^
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to participate in a fireside chat at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014, at 8:00 a.m. ET.
Sign-up for Sarepta Therapeutics to Present at Leerink Partners Rare Disease Roundtable investment picks
2014/10/1
On the heels of news of the first case of Ebola on U.S. soil, the company that has developed a treatment for the deadly disease said it has enough doses to cover about 100 patients.
Sign-up for Sarepta Therapeutics CEO: We have just 100 doses to treat Ebola investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers.
Sign-up for Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that it will give one oral presentation and two poster presentations on data from its ongoing Phase II and preclinical trials evaluating exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD) at the International Congress of the World Muscle Society (WMS), being held from October 7-11, 2014, in Berlin, Germany.
Sign-up for Sarepta Therapeutics Announces Presentations at the 19th International Congress of the World Muscle Society investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively.
Sign-up for Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy investment picks
By Erin McCarthy Sarepta Therapeutics Inc. said the U.S. Food and Drug Administration is requiring additional data for the new drug application for its Duchenne muscular dystrophy treatment eteplirsen.
Sign-up for Sarepta Therapeutics sees setback in Eteplirsen drug application investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sarepta’s NDA submission.
Sign-up for Sarepta Therapeutics Announces Regulatory Update on Eteplirsen investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and nine months ended September 30, 2014, and provided an update of recent corporate developments.
Sign-up for Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November.
Sign-up for Sarepta Therapeutics to Present Company Overview at Upcoming Conferences investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014.
Sign-up for Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) concerning possible violations of federal securities laws.
Sign-up for INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, December 2, 2014, beginning at 11:00 a.m. EST (8:00 a.m. PST / 4:00 p.m. GMT / 5:00 p.m. CET). Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer questions about Sarepta's DMD development program, including current and upcoming clinical trials.
Sign-up for Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November.
Sign-up for Sarepta Therapeutics to Present Company Overview at Upcoming Conferences investment picks
2014/11/18
SAN DIEGO and CAMBRIDGE, Mass.
Sign-up for Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Sarepta Therapeutics Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Saputo, Inc.  |  Next: ETFS Holding Sas AB